Business
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
MOUNTAIN VIEW, Calif., February 03, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Don
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/3ae655f6acb5dd50451ac8117451014b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WcCgb9Mi0gbNgB1c9yxSHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3ae655f6acb5dd50451ac8117451014b","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/zQgTS2Msz_dlPki9VlXeaw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/3ae655f6acb5dd50451ac8117451014b","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform –","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., February 03, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head of therapeutics, neuroscience at Janssen and a member of Alto’s board of directors.","length":719,"tagName":"p"},{"type":"text","content":"The article consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity—spanning synaptic, cellular, and circuit-level dysfunction—is a shared biological driver across multiple high-burden psychiatric disorders, including major depressive disorder, schizophrenia, PTSD, and addiction.","length":328,"tagName":"p"},{"type":"text","content":"The review concludes that therapeutic efficacy across pharmacologic, neuromodulatory, and behavioral interventions consistently converges on restoration of neuroplasticity, supporting plasticity as a causal, measurable, and druggable mechanism, rather than a...